c2.GRESHOCK CANCER COPY NUMBER UP c2.REACTOME VASOPRESSIN REGULATES RENAL WATER HOMEOSTASIS VIA AQUAPORINS c2.KEGG MEDICUS REFERENCE COHESIN DISSOCIATION IN ANAPHASE c2.KEGG MEDICUS REFERENCE ACH CHRN PI3K SIGNALING PATHWAY c2.REACTOME NGF STIMULATED TRANSCRIPTION c2.WP HEDGEHOG SIGNALING WP4249	le and epithelioid tumc	Gliomas	Glioneuronal tumors	
c2.PID FAS PATHWAY c2.REACTOME COLLAGEN BIOSYNTHESIS AND MODIFYING ENZYMES c2.TCGA GLIOBLASTOMA COPY NUMBER DN c2.KEGG MEDICUS PATHOGEN KSHV LANA TO WNT SIGNALING PATHWAY c2.TURJANSKI MAPK14 TARGETS c2.REACTOME SIGNALING BY SCF KIT c2.WP FGFR3 SIGNALING IN CHONDROCYTE PROLIFERATION AND TERMINAL DIFFERENTIATION c2.CHARAFE BREAST CANCER BASAL VS MESENCHYMAL DN c2.DER IFN ALPHA RESPONSE UP c2.REACTOME TRANSCRIPTIONAL REGULATION BY TP53 c2.NAKAMURA TUMOR ZONE PERIPHERAL VS CENTRAL DN c2.FEKIR HEPARG SIDE POP VS HEPARG UP c2.UDAYAKUMAR MED1 TARGETS DN c2.REACTOME CELL CYCLE CHECKPOINTS c2.HOSHIDA LIVER CANCER LATE RECURRENCE UP c2.KEGG TGF BETA SIGNALING PATHWAY				
C2.KEGG MEDICUS VARIANT MUTATION CAUSED ABERRANT HTT TO AUTOPHAGY VESICLE NÜCLEATION C2.KEGG MEDICUS VARIANT MUTATION ACTIVATED KIT TO PI3K SIGNALING PATHWAY C2.REACTOME PLATELET ACTIVATION SIGNALING AND AGGREGATION C2.KEGG MEDICUS REFERENCE AUTOPHAGOSOME AND LYSOSOME FUSION TETHERING FACTOR C2.WP MICRORNAS IN CARDIOMYOCYTE HYPERTROPHY C2.KEGG MEDICUS REFERENCE IRE1A JNK SIGNALING PATHWAY C2.KEGG MEDICUS REFERENCE MANNOSE TYPE O GLYCAN BIOSYNTHESIS FKTN TO LARGE C2.WP IL26 SIGNALING C2.WP INTRAFLAGELLAR TRANSPORT PROTEINS BINDING TO DYNEIN C2.MOOTHA MITOCHONDRIA C2.ELVIDGE HIF2A TARGETS UP C2.ASTON MAJOR DEPRESSIVE DISORDER UP C2.KEGG MEDICUS PATHOGEN KSHV VGPCR TO GNB G PI3K AKT SIGNALING PATHWAY C2.KEGG MEDICUS REFERENCE CXCR GNB G PI3K AKT SIGNALING PATHWAY				
c2.MATZUK MATERNAL EFFECT c2.WP TNFALPHA SIGNALING c2.MASRI RESISTANCE TO TAMOXIFEN AND AROMATASE INHIBITORS DN c2.WP DOPAMINE METABOLISM c2.LU TUMOR ANGIOGENESIS UP c2.KAN RESPONSE TO ARSENIC TRIOXIDE c2.UNTERMAN IPF VS CTRL B CELL DN c2.REACTOME CA2 PATHWAY c2.REACTOME CA2 PATHWAY c2.REACTOME SIGNALING BY INTERLEUKINS c2.WP SPHINGOLIPID METABOLISM IN SENESCENCE c2.REACTOME RECOGNITION OF DNA DAMAGE BY PCNA CONTAINING REPLICATION COMPLEX c2.KEGG SYSTEMIC LUPUS ERYTHEMATOSUS c2.HOLLEMAN ASPARAGINASE RESISTANCE ALL UP c2.REACTOME DDX58 IFIH1 MEDIATED INDUCTION OF INTERFERON ALPHA BETA c2.WAESCH ANAPHASE PROMOTING COMPLEX				
c2.PID RAS PATHWAY  c2.BLALOCK ALZHEIMERS DISEASE UP  c2.CONCANNON APOPTOSIS BY EPOXOMICIN UP  c2.PID BCR 5PATHWAY  c2.BIOCARTA LIS1 PATHWAY  c2.BIOCARTA LIS1 PATHWAY  c2.BIOCARTA LIS1 PATHWAY  c2.INAMURA LUNG CANCER SCC SUBTYPES UP  c2.INAMURA LUNG CANCER SCC SUBTYPES UP  c2.BIOCARTA MITR PATHWAY  c2.WP OVERLAP BETWEEN SIGNAL TRANSDUCTION PATHWAYS CONTRIBUTING TO LMNA LAMINOPATHIES  c2.YAO TEMPORAL RESPONSE TO PROGESTERONE CLUSTER 2  c2.CHIARADONNA NEOPLASTIC TRANSFORMATION KRAS CDC25 UP  c2.MARTINEZ RESPONSE TO TRABECTEDIN  c2.IVANOVSKA MIR106B TARGETS  c2.ROUSHMEHR GBM SOMATIC MUTATED  c2.REACTOME IKBA VARIANT LEADS TO EDA ID				
c2.CASORELLI ACUTE PROMYELOCYTIC LEUKEMIA UP c2.REACTOME GLYCOGEN METABOLISM c2.YAGI AML WITH T 9 11 TRANSLOCATION c2.GRYDER PAX3FOXO1 ENHANCERS KO DOWN c2.BROWNE HCMV INFECTION 10HR DN c2.BIOCARTA G1 PATHWAY c2.REACTOME POST TRANSLATIONAL PROTEIN MODIFICATION c2.WP GLYCEROLIPIDS AND GLYCEROPHOSPHOLIPIDS c2.REACTOME DOWNREGULATION OF ERBB2 SIGNALING c2.MELLMAN TUT1 TARGETS DN c2.REACTOME SIGNALING BY FGFR2 IIIA TM c2.PID RHOA REG PATHWAY c2.REACTOME PURINE RIBONUCLEOSIDE MONOPHOSPHATE BIOSYNTHESIS c2.KLEIN PRIMARY EFFUSION LYMPHOMA UP c2.DEBIASI APPOTOSIS BY REOVIRUS INFECTION UP				
c2.REACTOME RHOA GTPASE CYCLE c2.REACTOME GPVI MEDIATED ACTIVATION CASCADE c2.MCBRYAN TERMINAL END BUD DN c2.WP EFFECT OF OMEGA3 PUFA ON HUNTINGTONS DISEASE PATHWAYS c2.MYLLYKANGAS AMPLIFICATION HOT SPOT 27 c2.REACTOME TRISTETRAPROLIN TTP ZFP36 BINDS AND DESTABILIZES MRNA c2.BIOCARTA 41BB PATHWAY c2.REACTOME TFAP2 AP 2 FAMILY REGULATES TRANSCRIPTION OF CELL CYCLE FACTORS c2.BIOCARTA SLRP PATHWAY c2.SIG PIP3 SIGNALING IN B LYMPHOCYTES c2.SPIELMAN LYMPHOBLAST EUROPEAN VS ASIAN 2FC UP c2.REACTOME NRCAM INTERACTIONS c2.ZHONG RESPONSE TO AZACITIDINE AND TSA UP c2.WP HYPERTROPHY MODEL c2.REACTOME SUMOYLATION				
c2.WP NONSMALL CELL LUNG CANCER c2.VERHAAK GLIOBLASTOMA PRONEURAL c2.REACTOME GASTRULATION c2.CREIGHTON ENDOCRINE THERAPY RESISTANCE 5 c2.GUILLAUMOND KLF10 TARGETS UP c2.ROSS LEUKEMIA WITH MLL FUSIONS c2.KORKOLA EMBRYONAL CARCINOMA UP c2.SERVITJA ISLET HNF1A TARGETS UP c2.BIOCARTA SRCRPTP PATHWAY c2.BIOCARTA SRCRPTP PATHWAY c2.KEGG GLYCOLYSIS GLUCONEOGENESIS c2.WP NEURODEGENERATION WITH BRAIN IRON ACCUMULATION NBIA SUBTYPES PATHWAY c2.PID HNF3A PATHWAY c2.REACTOME CELL CELL COMMUNICATION c2.REACTOME ACTIVATION OF KAINATE RECEPTORS UPON GLUTAMATE BINDING c2.KEGG MEDICUS REFERENCE DISASSEMBLY OF MCC c2.WP DYRK1A INVOLVEMENT REGARDING CELL PROLIFERATION IN BRAIN DEVELOPMENT				
c2.NAKAMURA TUMOR ZONE PERIPHERAL VS CENTRAL UP c2.MOREAUX B LYMPHOCYTE MATURATION BY TACI DN c2.TONG INTERACT WITH PTTG1 c2.REACTOME RUNX3 REGULATES BCL2L11 BIM TRANSCRIPTION c2.REACTOME ADP SIGNALLING THROUGH P2Y PURINOCEPTOR 1 c2.REACTOME ADP SIGNALLING THROUGH P2Y PURINOCEPTOR 1 c2.RODRIGUES THYROID CARCINOMA POORLY DIFFERENTIATED UP c2.SCHLOSSER MYC AND SERUM RESPONSE SYNERGY c2.REACTOME DEATH RECEPTOR SIGNALING c2.BROWNE HCMV INFECTION 14HR UP c2.REACTOME MATURATION OF SARS COV 1 NUCLEOPROTEIN c2.KEGG PROGESTERONE MEDIATED OOCYTE MATURATION c2.REACTOME THROMBOXANE SIGNALLING THROUGH TP RECEPTOR c2.WANG SMARCE1 TARGETS UP c2.REACTOME TOXICITY OF BOTULINUM TOXIN TYPE D BOTD c2.REACTOMELLAGING KIDNEY NO BLOOD DN				
c2.HERNANDEZ MITOTIC ARREST BY DOCETAXEL 2 UP c2.BENPORATH NOS TARGETS c2.TOMIDA METASTASIS DN c2.RASHI RESPONSE TO IONIZING RADIATION 1 c2.KEGG MEDICUS PATHOGEN EBV EBNA1 TO P53 MEDIATED TRANSCRIPTION c2.KEGG VEGF SIGNALING PATHWAY c2.YAGI AML WITH T 8 21 TRANSLOCATION c2.REACTOME MYD88 INDEPENDENT TLR4 CASCADE c2.WP SPHINGOLIPID METABOLISM INTEGRATED PATHWAY c2.BIOCARTA ACH PATHWAY c2.JOHNSTONE PARVB TARGETS 3 DN c2.BLANCO MELO INFLUENZA A INFECTION A594 CELLS UP c2.REACTOME HIV TRANSCRIPTION ELONGATION c2.MURAKAMI UV RESPONSE 1HR DN c2.REACTOME SIGNALING BY FGFR2 IN DISEASE c2.REACTOME INTERLEUKIN 23 SIGNALING				
c2.REACTOME RESPONSE OF EIF2AK1 HRI TO HEME DEFICIENCY c2.ONGUSAHA BRCA1 TARGETS DN c2.KEGG WNT SIGNALING PATHWAY c2.WP FATTY ACID BETAOXIDATION c2.WANG BARRETTS ESOPHAGUS AND ESOPHAGUS CANCER UP c2.WP NEUROGENESIS REGULATION IN THE OLFACTORY EPITHELIUM c2.REACTOME PRESYNAPTIC FUNCTION OF KAINATE RECEPTORS c2.WP INTERLEUKIN1 INDUCED ACTIVATION OF NFKB c2.MOOTHA FFA OXYDATION c2.MATTIOLI MGUS VS MULTIPLE MYELOMA c2.WP NEURAL CREST CELL MIGRATION IN CANCER c2.SARTIPY NORMAL AT INSULIN RESISTANCE DN c2.KEGG MEDICUS REFERENCE TLR3 IRF3 SIGNALING PATHWAY c2.REACTOME APOPTOTIC FACTOR MEDIATED RESPONSE				
C2.REACTOME RAS ACTIVATION UPON CA2 INFLUX THROUGH NMDA RECEPTOR C2.LINDVALL IMMORTALIZED BY TERT DN C2.MUNSHI MULTIPLE MYELOMA DN C2.NAKAMURA METASTASIS C2.REACTOME TRANSPORT OF MATURE MRNAS DERIVED FROM INTRONLESS TRANSCRIPTS C2.WP AMPACTIVATED PROTEIN KINASE SIGNALING C2.KEGG ECM RECEPTOR INTERACTION C2.PID ERBB4 PATHWAY C2.SHAFFER IRF4 TARGETS IN ACTIVATED DENDRITIC CELL C2.SUBTIL PROGESTIN TARGETS C2.WP DISRUPTION OF POSTSYNAPTIC SIGNALING BY CNV C2.BRACHAT RESPONSE TO METHOTREXATE DN C2.WP MEVALONATE PATHWAY C2.BROWNE HCMV INFECTION 12HR DN C2.WP FERROPTOSIS				
c2.MYLLYKANGAS AMPLIFICATION HOT SPOT 16  c2.REACTOME INHIBITION OF REPLICATION INITIATION OF DAMAGED DNA BY RB1 E2F1  c2.REACTOME REGULATION OF TBK1 IKK IKBKE MEDIATED ACTIVATION OF IRF3 IRF7  c2.REACTOME NEGATIVE EPIGENETIC REGULATION OF RRNA EXPRESSION  c2.REACTOME TOFR1 MEDIATED CERAMIDE PRODUCTION  c2.REACTOME FOXO MEDIATED TRANSCRIPTION OF CELL DEATH GENES  c2.REACTOME SYNTHESIS SECRETION AND INACTIVATION OF GLUCAGON LIKE PEPTIDE 1 GLP 1  c2.KEGG MEDICUS VARIANT MUTATION ACTIVATED GNAS TO ACTH CORTISOL SIGNALING PATHWAY  c2.DELPUECH FOXO3 TARGETS UP  c2.KEGG N GLYCAN BIOSYNTHESIS  c2.ZHONG RESPONSE TO AZACITIDINE AND TSA DN  c2.MORI MATURE B LYMPHOCYTE DN  c2.KEGG MEDICUS VARIANT MUTATION INACTIVATED APC TO WNT SIGNALING PATHWAY  c2.BONOME OVARIAN CANCER SURVIVAL SUBOPTIMAL DEBULKING				
c2.BRUNO HEMATOPOIESIS c2.PUJANA ATM PCC NETWORK c2.KEGG MEDICUS VARIANT MUTATION CAUSED ABERRANT HTT TO EXTRINSIC APOPTOTIC PATHWAY c2.KEGG MEDICUS REFERENCE ITGA B RHOGAP RHOA SIGNALING PATHWAY c2.NEMETH INFLAMMATORY RESPONSE LPS UP c2.KEGG MEDICUS REFERENCE GLOBAL GENOME NER c2.JI CARCINOGENESIS BY KRAS AND STK11 DN c2.REACTOME NUCLEAR SIGNALING BY ERBB4 c2.REACTOME NETRIN 1 SIGNALING c2.PID AURORA B PATHWAY c2.KIM WT1 TARGETS UP c2.FRASOR RESPONSE TO SERM OR FULVESTRANT UP c2.REACTOME CD28 DEPENDENT VAV1 PATHWAY c2.REACTOME HIV LIFE CYCLE c2.BIOCARTA ARF PATHWAY c2.BLALOCK ALZHEIMERS DISEASE INCIPIENT UP				
c2.REACTOME PRE NOTCH PROCESSING IN THE ENDOPLASMIC RETICULUM c2.ACEVEDO NORMAL TISSUE ADJACENT TO LIVER TUMOR DN c2.EPPERT LSC R c2.HORTON SREBF TARGETS c2.KEGG MEDICUS REFERENCE CCR5 GNB G PLCB G PKC SIGNALING PATHWAY c2.BROWNE HCMV INFECTION 8HR UP c2.KEGG MEDICUS VARIANT FUS DDIT3 FUSION TO NFKB MEDIATED TRANSCRIPTION c2.REACTOME NOTCH4 INTRACELLULAR DOMAIN REGULATES TRANSCRIPTION c2.ROJIMA SFRP2 TARGETS DN c2.WANG TARGETS OF MLL CBP FUSION UP c2.HUMMERICH BENIGN SKIN TUMOR UP c2.PID TRAIL PATHWAY c2.WP EBSTEINBARR VIRUS LMP1 SIGNALING c2.WP SUPPRESSION OF HMGB1MEDIATED INFLAMMATION BY THBD c2.MAGRANGEAS MULTIPLE MYELOMA IGLL VS IGLK DN				
C2.DAZARD UV RESPONSE CLUSTER G3 C2.ROSS AML OF FAB M7 TYPE C2.SEITZ NEOPLASTIC TRANSFORMATION BY 8P DELETION DN C2.REACTOME FATTY ACYL COA BIOSYNTHESIS C2.WP ETHANOL METABOLISM PRODUCTION OF ROS BY CYP2E1 C2.KIM GLIS2 TARGETS UP C2.REACTOME POSTMITOTIC NUCLEAR PORE COMPLEX NPC REFORMATION C2.WP B CELL RECEPTOR SIGNALING C2.GROSS HYPOXIA VIA HIF1A DN C2.TSUNODA CISPLATIN RESISTANCE UP C2.REACTOME INTERACTIONS OF REV WITH HOST CELLULAR PROTEINS C2.PID ATF2 PATHWAY C2.BROWNE HCMV INFECTION 10HR UP C2.DAVICIONI TARGETS OF PAX FOXO1 FUSIONS UP C2.NOUZOVA TRETINOIN AND H4 ACETYLATION				
c2.REACTOME TRIGLYCERIDE METABOLISM c2.COATES MACROPHAGE M1 VS M2 UP c2.WP RESISTIN AS A REGULATOR OF INFLAMMATION c2.HADDAD T LYMPHOCYTE AND NK PROGENITOR UP c2.REACTOME MITOCHONDRIAL RNA DEGRADATION c2.REACTOME NEUROTOXICITY OF CLOSTRIDIUM TOXINS c2.REACTOME DNA DAMAGE TELOMERE STRESS INDUCED SENESCENCE c2.CHUNG BLISTER CYTOTOXICITY DN c2.FOROUTAN INTEGRATED TGFB EMT UP c2.OUELLET CULTURED OVARIAN CANCER INVASIVE VS LMP DN c2.MOOTHA GLYCOGEN METABOLISM c2.MARSON BOUND BY FOXP3 STIMULATED c2.KEGG MEDICUS REFERENCE LPA GNAQ 11 RHOA SIGNALING PATHWAY c2.REACTOME REGULATION OF PYRUVATE DEHYDROGENASE PDH COMPLEX c2.WP IL17 SIGNALING				
c2.GINESTIER BREAST CANCER ZNF217 AMPLIFIED DN c2.NAKAMURA ADIPOGENESIS EARLY DN c2.BASAKI YBX1 TARGETS DN c2.KEGG MEDICUS REFERENCE BCR PLCG CALCINEURIN SIGNALING PATHWAY c2.WP CALCIUM MEDIATED TCELL APOPTOSIS INVOLVED IN INCLUSION BODY MYOSITIS c2.PID CD8 TCR DOWNSTREAM PATHWAY c2.WP CANCER IMMUNOTHERAPY BY CTLA4 BLOCKADE c2.CARRILLOREIXACH MRS3 VS LOWER RISK HEPATOBLASTOMA DN c2.DELLA RESPONSE TO TSA AND BUTYRATE c2.REACTOME TNFR1 INDUCED NF KAPPA B SIGNALING PATHWAY c2.GARGALOVIC RESPONSE TO OXIDIZED PHOSPHOLIPIDS BLACK UP c2.JIANG MELANOMA TRM2 CD8 c2.REACTOME CYTOCHROME C MEDIATED APOPTOTIC RESPONSE c2.IIZUKA LIVER CANCER PROGRESSION LO L1 UP c2.HOFMANN MYELODYSPLASTIC SYNDROM HIGH RISK UP				
c2.WP IL18 SIGNALING c2.SETLUR PROSTATE CANCER TMPRSS2 ERG FUSION UP c2.COLLIS PRKDC SUBSTRATES c2.SHEPARD BMYB MORPHOLINO UP c2.SASAKI ADULT T CELL LEUKEMIA c2.CROONQUIST NRAS VS STROMAL STIMULATION DN c2.REACTOME TRAF3 DEPENDENT IRF ACTIVATION PATHWAY c2.ENK UV RESPONSE EPIDERMIS DN c2.REACTOME DEPOLYMERIZATION OF THE NUCLEAR LAMINA c2.DACOSTA UV RESPONSE VIA ERCC3 UP c2.RUTELLA RESPONSE TO HGF UP c2.REACTOME INTEGRATION OF ENERGY METABOLISM c2.GRAESSMANN RESPONSE TO MC AND DOXORUBICIN DN c2.CINIG LUNG CANCER MUTATED SIGNIFICANTLY c2.KEGG MEDICUS ENV FACTOR NICOTINE TO JAK STAT SIGNALING PATHWAY				
c2.REACTOME COLLAGEN DEGRADATION c2.AMUNDSON DNA DAMAGE RESPONSE TP53 c2.REACTOME NUCLEOTIDE EXCISION REPAIR c2.KEGG GLYOXYLATE AND DICARBOXYLATE METABOLISM c2.ONDER CDH1 TARGETS 1 DN c2.BIOCARTA ERBB4 PATHWAY c2.BYSTRYKH HEMATOPOIESIS STEM CELL SCP2 QTL TRANS c2.REACTOME HEMOSTASIS c2.LEE METASTASIS AND ALTERNATIVE SPLICING DN c2.REACTOME NOD1 2 SIGNALING PATHWAY c2.HEBERT MATRISOME TNBC BRAIN METASTASIS TUMOR CELL DERIVED c2.REACTOME SUMOYLATION OF RNA BINDING PROTEINS c2.WP TNFRELATED WEAK INDUCER OF APOPTOSIS TWEAK SIGNALING c2.CHEOK RESPONSE TO HD MTX UP c2.WP OMEGA3 OMEGA6 FATTY ACID SYNTHESIS				
c2.GOBERT CORE OLIGODENDROCYTE DIFFERENTIATION c2.WP REGULATION OF APOPTOSIS BY PARATHYROID HORMONERELATED PROTEIN c2.WILLIAMS ESR2 TARGETS UP c2.WANG HCP PROSTATE CANCER c2.PETROVA ENDOTHELIUM LYMPHATIC VS BLOOD DN c2.DORN ADENOVIRUS INFECTION 32HR UP c2.CHEN LVAD SUPPORT OF FAILING HEART UP c2.BAKER HEMATOPOIESIS STAT3 TARGETS c2.WU HBX TARGETS 1 UP c2.WP TCELL ANTIGEN RECEPTOR TCR PATHWAY DURING STAPHYLOCOCCUS AUREUS INFECTION c2.REACTOME DOWNSTREAM SIGNALING OF ACTIVATED FGF11 c2.BYSTRYKH HEMATOPOIESIS STEM CELL QTL TRANS c2.REACTOME EPH EPHRIN MEDIATED REPULSION OF CELLS c2.REACTOME SARS COV 2 ACTIVATES MODULATES INNATE AND ADAPTIVE IMMUNE RESPONSES c2.SAKAI TUMOR INFILTRATING MONOCYTES UP c2.MORI PRE BI LYMPHOCYTE DN				
c2.MORI PRE BI LYMPHOCYTE DN c2.REACTOME WAX AND PLASMALOGEN BIOSYNTHESIS c2.HELLER HDAC TARGETS SILENCED BY METHYLATION UP c2.REACTOME SUMOYLATION OF DNA REPLICATION PROTEINS c2.LASTOWSKA NEUROBLASTOMA COPY NUMBER UP c2.CUI TCF21 TARGETS 2 DN c2.KEGG FATTY ACID METABOLISM c2.STEINER ERYTHROCYTE MEMBRANE GENES c2.SMITH TERT TARGETS DN c2.RICKMAN TUMOR DIFFERENTIATED WELL VS POORLY UP c2.GAUSSMANN MLL AF4 FUSION TARGETS B DN c2.WAKABAYASHI ADIPOGENESIS PPARG RXRA BOUND 8D c2.KEGG MEDICUS REFERENCE DEUBIQUITINATION OF H2AK119 c2.LINDGREN BLADDER CANCER WITH LOH IN CHR9Q c2.REACTOME REGULATION OF INSULIN SECRETION c2.WP MITOCHONDRIAL FATTY ACID OXIDATION DISORDERS				
c2.WP MITOCHONDRIAL FATTY ACID OXIDATION DISORDERS c2.REACTOME RUNX2 REGULATES BONE DEVELOPMENT c2.REACTOME REGULATION OF NF KAPPA B SIGNALING c2.PID P38 MKK3 6PATHWAY c2.BURTON ADIPOGENESIS PEAK AT 8HR c2.WP FATTY ACID TRANSPORTERS c2.SCHRAETS MLL TARGETS DN c2.RODRIGUES THYROID CARCINOMA DN c2.CHARAFE BREAST CANCER LUMINAL VS BASAL DN c2.BENPORATH OCT4 TARGETS c2.DEURIG T CELL PROLYMPHOCYTIC LEUKEMIA DN c2.REACTOME GLYCOSPHINGOLIPID TRANSPORT c2.CROMER METASTASIS DN c2.LINSLEY MIR16 TARGETS c2.PID NFKAPPAB CANONICAL PATHWAY c2.KEGG MEDICUS REFERENCE MEMBRANE INITIATED PROGESTERONE SIGNALING PATHWAY				
C2.KEGG MEDICUS VARIANT EGF OVEREXPRESSION TO PI3K SIGNALING PATHWAY C2.REACTOME NFE2L2 REGULATING MDR ASSOCIATED ENZYMES C2.RASHI RESPONSE TO IONIZING RADIATION 2 C2.PALOMERO GSI SENSITIVITY UP C2.FIRESTEIN CTNNB1 PATHWAY AND PROLIFERATION C2.BIOCARTA D4GDI PATHWAY C2.WEINMANN ADAPTATION TO HYPOXIA DN C2.BIOCARTA TNFR1 PATHWAY C2.KEGG MEDICUS VARIANT MUTATION INACTIVATED RASD1 TO CRHR PKA ACTH SIGNALING PATHWAY C2.KAAB HEART ATRIUM VS VENTRICLE DN C2.REACTOME CREB PHOSPHORYLATION C2.AMIT EGF RESPONSE 60 MCF10A C2.REACTOME RNA POLYMERASE II PRE TRANSCRIPTION EVENTS C2.KEGG CHEMOKINE SIGNALING PATHWAY C2.SIG CD40PATHWAYMAP C2.HINATA NFKB TARGETS FIBROBLAST UP				
c2.REACTOME ABERRANT REGULATION OF MITOTIC G1 S TRANSITION IN CANCER DUE TO RB1 DEFECTS c2.JACKSON DNMT1 TARGETS DN c2.PASQUALLUCI LYMPHOMA BY GC STAGE UP c2.RASHI RESPONSE TO IONIZING RADIATION 4 c2.BANDRES RESPONSE TO CARMUSTIN WITHOUT MGMT 24HR UP c2.MCCLUNG CREB1 TARGETS DN c2.KEGG BLADDER CANCER c2.REACTOME OVARIAN TUMOR DOMAIN PROTEASES c2.FRASOR TAMOXIFEN RESPONSE UP c2.MULLIGHAN NPM1 MUTATED SIGNATURE 2 DN c2.KEGG FC EPSILON RI SIGNALING PATHWAY c2.IGARASHI ATF4 TARGETS DN c2.IM SREBF1A TARGETS c2.EHLERS ANEUPLOIDY UP c2.YAMANAKA GLIOBLASTOMA SURVIVAL DN				
c2.REACTOME TRANSCRIPTION COUPLED NUCLEOTIDE EXCISION REPAIR TC NER c2.BECKER TAMOXIFEN RESISTANCE UP c2.GARGALOVIC RESPONSE TO OXIDIZED PHOSPHOLIPIDS LIGHTYELLOW UP c2.HAN SATB1 TARGETS UP c2.WP SARSCOV2 ALTERING ANGIOGENESIS VIA NRP1 c2.PID TNF PATHWAY c2.PID TNF PATHWAY c2.FOROUTAN TGFB EMT UP c2.BIOCARTA SET PATHWAY c2.VALK AML WITH EVI1 c2.WP MITOCHONDRIAL LONG CHAIN FATTY ACID BETAOXIDATION c2.KEGG MEDICUS REFERENCE PDL PD1 SHP PI3K SIGNALING PATHWAY c2.DELASERNA MYOD TARGETS UP c2.HUANG FOXA2 TARGETS DN c2.REACTOME CDC42 GTPASE CYCLE c2.WP TRIACYLGLYCERIDE SYNTHESIS				
c2.OLSSON E2F3 TARGETS UP c2.PID P38 ALPHA BETA PATHWAY  c2.FOROUTAN PRODRANK TGFB EMT UP c2.REACTOME REGULATED NECROSIS c2.KEGG PYRUVATE METABOLISM c2.BLUM RESPONSE TO SALIRASIB DN c2.VALK AML CLUSTER 9 c2.MORI LARGE PRE BII LYMPHOCYTE UP c2.REACTOME HEME SIGNALING c2.ZHU SKIL TARGETS DN c2.ONDER CDH1 SIGNALING VIA CTNNB1 c2.OSWALD HEMATOPOIETIC STEM CELL IN COLLAGEN GEL UP c2.REACTOME TRANSPORT OF THE SLBP DEPENDANT MATURE MRNA c2.KEGG MEDICUS REFERENCE CA2 CAM CAMK SIGNALING PATHWAY c2.SHAFFER IRF4 TARGETS IN PLASMA CELL VS MATURE B LYMPHOCYTE c2.REACTOME ION TRANSPORT BY P TYPE ATPASES				
c2.WP UNFOLDED PROTEIN RESPONSE c2.LA MEN1 TARGETS c2.KORKOLA SEMINOMA UP c2.REACTOME EXTRACELLULAR MATRIX ORGANIZATION c2.XU AKT1 TARGETS 6HR c2.REACTOME GENE SILENCING BY RNA c2.REACTOME GENE SILENCING BY RNA c2.RODRIGUES THYROID CARCINOMA ANAPLASTIC DN c2.WP PEROXIREDOXIN 2 INDUCED OVARIAN FAILURE c2.WP KISSPEPTINKISSPEPTIN RECEPTOR SYSTEM IN THE OVARY c2.KEGG MEDICUS REFERENCE RIG I NFKB SIGNALING PATHWAY c2.REACTOME MECP2 REGULATES NEURONAL RECEPTORS AND CHANNELS c2.WP LEPTININSULIN SIGNALING OVERLAP c2.RIZKI TUMOR INVASIVENESS 2D UP c2.WP MIR124 PREDICTED INTERACTIONS WITH CELL CYCLE AND DIFFERENTIATION c2.REACTOME SUMOYLATION OF DNA METHYLATION PROTEINS				
c2.HORIUCHI WTAP TARGETS DN c2.PID TXA2PATHWAY c2.KOHOUTEK CCNT1 TARGETS c2.REACTOME NFE2L2 REGULATING TUMORIGENIC GENES c2.REACTOME NFE2L2 REGULATING TUMORIGENIC GENES c2.REACTOME ACTIVATION OF IRF3 IRF7 MEDIATED BY TBK1 IKK IKBKE c2.TSENG ADIPOGENIC POTENTIAL DN c2.MA MYELOID DIFFERENTIATION DN c2.SESTO RESPONSE TO UV C3 c2.REACTOME CYTOKINE SIGNALING IN IMMUNE SYSTEM c2.REACTOME GLOBAL GENOME NUCLEOTIDE EXCISION REPAIR GG NER c2.WONG ADULT TISSUE STEM MODULE c2.REACTOME CREATION OF C4 AND C2 ACTIVATORS c2.OUYANG PROSTATE CANCER MARKERS				
c2.MOREAUX MULTIPLE MYELOMA BY TACI DN c2.BILBAN B CLL LPL UP c2.NABA COLLAGENS c2.REACTOME COLLAGEN CHAIN TRIMERIZATION c2.CUI GLUCOSE DEPRIVATION c2.CUI GLUCOSE DEPRIVATION c2.REACTOME SUMOYLATION OF IMMUNE RESPONSE PROTEINS c2.MARZEC IL2 SIGNALING DN c2.SMID BREAST CANCER RELAPSE IN PLEURA UP c2.WP CHEMOKINE SIGNALING c2.WP ARYL HYDROCARBON RECEPTOR PATHWAY WP2873 c2.CHANGOLKAR H2AFY TARGETS DN c2.WP SPHINGOLIPID METABOLISM OVERVIEW c2.REACTOME COSTIMULATION BY THE CD28 FAMILY c2.KYNG DNA DAMAGE BY 4NQO OR GAMMA RADIATION c2.HASLINGER B CLL WITH 11Q23 DELETION c2.NIKOLSKY BREAST CANCER 12Q13 Q21 AMPLICON				
c2.JAIN NFKB SIGNALING c2.KEGG MEDICUS REFERENCE GENE SILENCING BY METHYLATION OF H3K27 AND UBIQUITINATION OF H2AK119 c2.REACTOME AQUAPORIN MEDIATED TRANSPORT c2.BIOCARTA IL22BP PATHWAY c2.WANG CISPLATIN RESPONSE AND XPC DN c2.RUTELLA RESPONSE TO CSF2RB AND IL4 UP c2.KEGG MEDICUS REFERENCE LPAR GNB G RHO SIGNALING PATHWAY c2.REACTOME RNA POLYMERASE III TRANSCRIPTION c2.CHEN PDGF TARGETS c2.WANG PROSTATE CANCER ANDROGEN INDEPENDENT c2.ZWANG EGF PERSISTENTLY UP c2.POS HISTAMINE RESPONSE NETWORK c2.SARTIPY NORMAL AT INSULIN RESISTANCE UP c2.KEGG MEDICUS VARIANT MUTATION CAUSED ABERRANT HTT TO CREB MEDIATED TRANSCRIPTION c2.YAO TEMPORAL RESPONSE TO PROGESTERONE CLUSTER 1				
c2.REACTOME DEGRADATION OF THE EXTRACELLULAR MATRIX c2.NIKOLSKY BREAST CANCER 20Q11 AMPLICON c2.WEI MIR34A TARGETS c2.PID AMB2 NEUTROPHILS PATHWAY c2.REACTOME SHC1 EVENTS IN EGFR SIGNALING c2.JINESH BLEBBISHIELD TRANSFORMED STEM CELL SPHERES UP c2.WP ENERGY METABOLISM c2.REACTOME THE NLRP3 INFLAMMASOME c2.FORTSCHEGGER PHF8 TARGETS DN c2.REACTOME PTK6 PROMOTES HIF1A STABILIZATION c2.KIM PTEN TARGETS UP c2.CARRILLOREIXACH HEPATOBLASTOMA VS NORMAL HYPOMETHYLATED AND UP c2.KEGG MEDICUS PATHOGEN HPV E6 TO NOTCH SIGNALING PATHWAY N00382 c2.REACTOME ZINC INFLUX INTO CELLS BY THE SLC39 GENE FAMILY				
c2.PID PTP18 PATHWAY c2.KEGG MEDICUS REFERENCE REGULATION OF TNF NFKB SIGNALING PATHWAY LUBAC MEDIATED LINEAR UBIQUITINATION c2.WP FAS LIGAND PATHWAY AND STRESS INDUCTION OF HEAT SHOCK PROTEINS c2.KEGG VASCULAR SMOOTH MUSCLE CONTRACTION c2.REACTOME RSV HOST INTERACTIONS c2.CEBALLOS TARGETS OF TP53 AND MYC DN c2.SCHLINGEMANN SKIN CARCINOGENESIS TPA DN c2.JACKSON DNMT1 TARGETS UP c2.ZHANG RESPONSE TO CANTHARIDIN UP c2.BORLAK LIVER CANCER EGF UP c2.LENAOUR DENDRITIC CELL MATURATION DN c2.SCHLINGEMANN SKIN CARCINOGENESIS TPA UP c2.REACTOME NS1 MEDIATED EFFECTS ON HOST PATHWAYS c2.REACTOME NS1 MEDIATED EFFECTS OF TITCH AND SUFU DN c2.REACTOME RAC1 GTPASE CYCLE				patho_cat_name
c2.NABA MATRISOME HIGHLY METASTATIC MELANOMA TUMOR CELL DERIVED c2.REACTOME GLUCOSE METABOLISM c2.REACTOME REDUCTION OF CYTOSOLIC CA LEVELS c2.KEGG MEDICUS VARIANT ERBB2 OVEREXPRESSION TO PI3K SIGNALING PATHWAY c2.WP WNT SIGNALING AND PLURIPOTENCY c2.REACTOME MRNA CAPPING c2.BROWNE HCMV INFECTION 18HR UP c2.REACTOME IONOTROPIC ACTIVITY OF KAINATE RECEPTORS c2.TSAI DNAJB4 TARGETS DN c2.BARRIER CANCER RELAPSE TUMOR SAMPLE DN c2.TERAMOTO OPN TARGETS CLUSTER 4 c2.REACTOME CELL CYCLE c2.HEBERT MATRISOME TINBC BRAIN METASTASIS c2.REACTOME CELL DEATH SIGNALLING VIA NRAGE NRIF AND NADE c2.SHIPP DLBCL CURED VS FATAL DN				Nerve sheath tumors Spindle and epithelioid tumors Gliomas Glioneuronal tumors
c2.GARGALOVIC RESPONSE TO OXIDIZED PHOSPHOLIPIDS LIGHTGREEN DN c2.DONATO CELL CYCLE TRETINOIN c2.AKL HTLV1 INFECTION DN c2.RORIE TARGETS OF EWSR1 FLI1 FUSION UP c2.SENGUPTA NASOPHARYNGEAL CARCINOMA WITH LMP1 UP c2.WP ENDOCHONDRAL OSSIFICATION c2.WP ENDOCHONDRAL OSSIFICATION WITH SKELETAL DYSPLASIAS c2.HASINA NOL7 TARGETS DN c2.GROSS HYPOXIA VIA ELK3 DN c2.REACTOME DUAL INCISION IN TC NER c2.REACTOME TRAF6 MEDIATED INDUCTION OF TAK1 COMPLEX WITHIN TLR4 COMPLEX c2.YAMAZAKI TCEB3 TARGETS DN c2.TSENG IRS1 TARGETS UP c2.TOMLINS METASTASIS DN c2.MARSON BOUND BY FOXP3 UNSTIMULATED				
C2.BHATI G2M ARREST BY 2METHOXYESTRADIOL UP C2.CHIN BREAST CANCER COPY NUMBER UP C2.LE SKI TARGETS UP C2.ROESSLER LIVER CANCER METASTASIS DN C2.ONDER CDH1 TARGETS 1 UP C2.WP MAMMARY GLAND DEVELOPMENT INVOLUTION STAGE 4 OF 4 C2.WATANABE ULCERATIVE COLITIS WITH CANCER UP C2.SMITH LIVER CANCER C2.DODD NASOPHARYNGEAL CARCINOMA UP C2.KUUSELO PANCREATIC CANCER 19Q13 AMPLIFICATION C2.TSAI DNAJB4 TARGETS UP C2.WP FATTY ACIDS AND LIPOPROTEINS TRANSPORT IN HEPATOCYTES C2.REACTOME MITOTIC SPINDLE CHECKPOINT C2.WILLETTE CLL 13Q14 DELETION UP C2.REACTOME FORMATION OF THE EARLY ELONGATION COMPLEX C2.WP CHOLESTEROL METABOLISM WITH BLOCH AND KANDUTSCHRUSSELL PATHWAYS				
c2.PEDERSEN METASTASIS BY ERBB2 ISOFORM 5				
c2.REACTOME INTERLEUKIN 6 FAMILY SIGNALING  c2.REACTOME OF RUNY SIGNALING  c2.WAKABAYASHI ADIPOGENESIS PPARG RXRA BOUND 36HR  c2.REACTOME INTERLEUKIN 6 FAMILY SIGNALING  c2.WAKABAYASHI ADIPOGENESIS PPARG RXRA BOUND 36HR  c2.REACTOME INTERLEUKIN 6 FAMILY SIGNALING  c2.LIN MELANOMA COPY NUMBER UP  c2.TONKS TARGETS OF RUNX1 RUNX1T1 FUSION HSC UP  c2.WP IMATINIB AND CHRONIC MYELOID LEUKEMIA  c2.REACTOME TOLL LIKE RECEPTOR 9 TLR9 CASCADE  c2.REACTOME INTERLEUKIN 7 SIGNALING				
C2.BROWNE HCMV INFECTION 16HR DN C2.KEGG OLFACTORY TRANSDUCTION C2.REACTOME PLASMA LIPOPROTEIN ASSEMBLY C2.WP PROGERIAASSOCIATED LIPODYSTROPHY C2.REACTOME APOPTOSIS INDUCED DNA FRAGMENTATION C2.KERLEY RESPONSE TO CISPLATIN DN C2.KERLEY RESPONSE TO CISPLATIN DN C2.REACTOME ADIPOGENESIS C2.WP DRAVET SYNDROME C2.YAGI AML WITH 11Q23 REARRANGED C2.FEVR CTNNB1 TARGETS DN C2.CHUANG OXIDATIVE STRESS RESPONSE DN C2.ELVIDGE HIF1A AND HIF2A TARGETS DN C2.KEGG MEDICUS REFERENCE ITGA B RHOGEF RHOA SIGNALING PATHWAY C2.BOYLAN MULTIPLE MYELOMA C DN				
C2.BILANGES RAPAMYCIN SENSITIVE GENES C2.REACTOME ACTIVATED NTRK2 SIGNALS THROUGH CDK5 C2.MCBRYAN PUBERTAL BREAST 6 7WK DN C2.SENESE HDAC1 TARGETS DN C2.KAAB FAILED HEART ATRIUM UP C2.BERENJENO TRANSFORMED BY RHOA REVERSIBLY DN C2.REACTOME CYTOSOLIC TRNA AMINOACYLATION C2.REACTOME MEIOTIC SYNAPSIS C2.MORI PRE BI LYMPHOCYTE UP C2.WP 13Q1212 COPY NUMBER VARIATION C2.NABA MATRISOME POORLY METASTATIC MELANOMA C2.YAGI AML FAB MARKERS C2.GOUYER TATI TARGETS DN C2.WP HYPOTHETICAL CRANIOFACIAL DEVELOPMENT PATHWAY C2.KEGG VALINE LEUCINE AND ISOLEUCINE DEGRADATION				
C2.BIOCARTA PLCD PATHWAY  C2.BLANCO MELO COVID19 SARS COV 2 INFECTION A594 ACE2 EXPRESSING CELLS RUXOLITINIB DN  C2.RUTELLA RESPONSE TO HGF VS CSF2RB AND IL4 UP  C2.REACTOME REGULATION OF CDH11 GENE TRANSCRIPTION  C2.YAO HOXA10 TARGETS VIA PROGESTERONE UP  C2.BUCKANOVICH T LYMPHOCYTE HOMING ON TUMOR UP  C2.WP PHOSPHOINOSITIDES METABOLISM  C2.PID AP1 PATHWAY  C2.ELVIDGE HYPOXIA BY DMOG UP  C2.SARTIPY BLUNTED BY INSULIN RESISTANCE DN  C2.KEGG MEDICUS PATHOGEN HTLV 1 TAX TO SPINDLE ASSEMBLY CHECKPOINT SIGNALING  C2.LIANG HEMATOPOIESIS STEM CELL NUMBER QTL  C2.CHICAS RB1 TARGETS CONFLUENT  C2.KEGG MEDICUS REFERENCE IL10 FAMILY TO JAK STAT SIGNALING PATHWAY  C2.WP MYOMETRIAL RELAXATION AND CONTRACTION PATHWAYS  C2.DUTERTRE ESTRADIOL RESPONSE 24HR DN				
C2.LOPEZ MESOTHELIOMA SURVIVAL WORST VS BEST UP C2.SCHAEFFER PROSTATE DEVELOPMENT AND CANCER BOX2 DN C2.GRADE COLON VS RECTAL CANCER DN C2.REACTOME VIRAL MESSENGER RNA SYNTHESIS C2.REACTOME SUMOYLATION OF UBIQUITINYLATION PROTEINS C2.KAUFFMANN MELANOMA RELAPSE DN C2.REACTOME REACTIONS SPECIFIC TO THE COMPLEX N GLYCAN SYNTHESIS PATHWAY C2.BIOCARTA PLATELETAPP PATHWAY C2.KEGG MEDICUS REFERENCE EGF JAK STAT SIGNALING PATHWAY C2.EHLERS ANEUPLOIDY DN C2.KEGG MEDICUS VARIANT CYP11B1 CYP11B2 FUSION TO ACTH CORTISOL SIGNALING PATHWAY C2.KUWANO RNA STABILIZED BY NO C2.MIZUSHIMA AUTOPHAGOSOME FORMATION C2.KEGG MEDICUS REFERENCE MLK JNK SIGNALING PATHWAY C2.GENTILE UV LOW DOSE UP C2.REACTOME SUMOYLATION OF DNA DAMAGE RESPONSE AND REPAIR PROTEINS				
C2.REACTOME SOMOTLATION OF DINA DAIRINGS EAST-ONSE AND REPAIR FROTEINS  C2.KEGG CYSTEINE AND METHIONINE METABOLISM  C2.BLANCO MELO MERS COV INFECTION MCR5 CELLS DN  C2.GAZDA DIAMOND BLACKFAN ANEMIA MYELOID UP  C2.REACTOME LGI ADAM INTERACTIONS  C2.KARAKAS TGFB1 SIGNALING  C2.KEGG GLYCOSAMINOGLYCAN BIOSYNTHESIS KERATAN SULFATE  C2.REACTOME AURKA ACTIVATION BY TPX2  C2.REACTOME NEUROTRANSMITTER RECEPTORS AND POSTSYNAPTIC SIGNAL TRANSMISSION  C2.LEE LIVER CANCER MYC E2F1 UP  C2.KEGG T CELL RECEPTOR SIGNALING PATHWAY  C2.TAGHAVI NEOPLASTIC TRANSFORMATION  C2.CASTELLANO HRAS TARGETS DN  C2.REACTOME PLASMA LIPOPROTEIN ASSEMBLY REMODELING AND CLEARANCE				
C2.REACTOME GLYCEROPHOSPHOLIPID CATABOLISM C2.REACTOME NUCLEOTIDE BINDING DOMAIN LEUCINE RICH REPEAT CONTAINING RECEPTOR NLR SIGNALING PATHWAYS C2.REACTOME MITOTIC PROMETAPHASE C2.LE EGR2 TARGETS UP C2.SASAI TARGETS OF CXCR6 AND PTCH1 DN C2.RATTENBACHER BOUND BY CELF1 C2.WILLIAMS ESR2 TARGETS DN C2.CAMPS COLON CANCER COPY NUMBER UP C2.HOLLEMAN VINCRISTINE RESISTANCE B ALL UP C2.KEGG MEDICUS VARIANT EML4 ALK FUSION KINASE TO PI3K SIGNALING PATHWAY C2.BACOLOD RESISTANCE TO ALKYLATING AGENTS UP C2.REACTOME TYPE I HEMIDESMOSOME ASSEMBLY C2.WP THERMOGENESIS C2.KEGG MEDICUS VARIANT MUTATION INACTIVATED PRKN TO INTRINSIC APOPTOTIC PATHWAY C2.IVANOVA HEMATOPOIESIS MATURE CELL C2.KASLER HDAC7 TARGETS 2 DN				
c2.PRAMOONJAGO SOX4 TARGETS UP c2.WP NEURAL CREST CELL MIGRATION DURING DEVELOPMENT c2.BOYLAN MULTIPLE MYELOMA C CLUSTER DN c2.WP PROTEOGLYCAN BIOSYNTHESIS c2.LIU IL13 PRIMING MODEL c2.REACTOME PROTEIN LOCALIZATION c2.KYNG ENVIRONMENTAL STRESS RESPONSE NOT BY 4NQO IN OLD c2.KEGG CELL CYCLE c2.FRASOR RESPONSE TO ESTRADIOL DN c2.MARTORIATI MDM4 TARGETS NEUROEPITHELIUM UP c2.KEGG MEDICUS REFERENCE HEPARAN SULFATE BIOSYNTHESIS c2.CHUANG OXIDATIVE STRESS RESPONSE UP c2.PID CERAMIDE PATHWAY c2.KEGG MEDICUS REFERENCE ITGA B RHOG RAC SIGNALING PATHWAY c2.REACTOME CARGO TRAFFICKING TO THE PERICILIARY MEMBRANE c2.REACTOME CARGO TRAFFICKING TO THE PERICILIARY MEMBRANE				
c2.SCHUHMACHER MYC TARGETS UP c2.KANG CISPLATIN RESISTANCE UP c2.LAU APOPTOSIS CDKN2A UP c2.REACTOME SYNTHESIS OF PG c2.PILON KLF1 TARGETS UP c2.REACTOME ADRENALINE NORADRENALINE INHIBITS INSULIN SECRETION c2.WP METABOLIC EPILEPTIC DISORDERS c2.BIOCARTA ALK PATHWAY c2.GALE APL WITH FLT3 MUTATED UP c2.LINDGREN BLADDER CANCER CLUSTER 2B c2.HEBERT MATRISOME TNBC LUNG METASTASIS TUMOR CELL DERIVED c2.COLDREN GEFITINIB RESISTANCE UP c2.LKEDA MIR133 TARGETS DN c2.DELACROIX RARG BOUND MEF c2.WP CIRCADIAN RHYTHM GENES				
c2.VANDESLUIS COMMD1 TARGETS GROUP 2 UP c2.CAMPS COLON CANCER COPY NUMBER DN c2.ZIRN TRETINOIN RESPONSE DN c2.REACTOME TRANSCRIPTION OF THE HIV GENOME c2.YIH RESPONSE TO ARSENITE C3 c2.GAUSSMANN MLL AF4 FUSION TARGETS A UP c2.WP KCNQ2RELATED EPILEPSIES c2.MRATENS TRETINOIN RESPONSE DN c2.REACTOME RECRUITMENT OF MITOTIC CENTROSOME PROTEINS AND COMPLEXES c2.REACTOME SIGNALING BY MEMBRANE TETHERED FUSIONS OF PDGFRA OR PDGFRB c2.BIOCARTA TOLL PATHWAY c2.PID IL2 STAT5 PATHWAY c2.WP ACETYLCHOLINE SYNTHESIS c2.DIAZ CHRONIC MYELOGENOUS LEUKEMIA DN c2.SENESE HDAC3 TARGETS DN c2.DOUGLAS BMI1 TARGETS UP				
C2.PETRETTO LEFT VENTRICLE MASS QTL CIS UP C2.REACTOME TP53 REGULATES TRANSCRIPTION OF GENES INVOLVED IN G2 CELL CYCLE ARREST C2.WP RELATIONSHIP BETWEEN INFLAMMATION COX2 AND EGFR C2.EPPERT PROGENITOR C2.BIOCARTA STRESS PATHWAY C2.SMID BREAST CANCER RELAPSE IN LUNG UP C2.WP HIPPOCAMPAL SYNAPTOGENESIS AND NEUROGENESIS C2.REACTOME ACTIVATION OF NIMA KINASES NEK9 NEK6 NEK7 C2.WP CELL CYCLE C2.YEMELYANOV GR TARGETS DN C2.REACTOME PKA MEDIATED PHOSPHORYLATION OF KEY METABOLIC FACTORS C2.REACTOME REGULATION OF MITF M DEPENDENT GENES INVOLVED IN PIGMENTATION C2.GAUSSMANN MLL AF4 FUSION TARGETS C UP C2.INGRAM SHH TARGETS UP C2.HUTTMANN B CLL POOR SURVIVAL UP				
c2.BIOCARTA IFNA PATHWAY c2.WP CATABOLISM OF SKELETAL MUSCLE IN CACHEXIA c2.ZWANG CLASS 2 TRANSIENTLY INDUCED BY EGF c2.PID UPA UPAR PATHWAY c2.REACTOME RRNA MODIFICATION IN THE NUCLEUS AND CYTOSOL c2.MCGOWAN RSP6 TARGETS UP c2.REACTOME CYCLIN A B1 B2 ASSOCIATED EVENTS DURING G2 M TRANSITION c2.LU EZH2 TARGETS DN c2.CAFFAREL RESPONSE TO THC DN c2.LINDGREN BLADDER CANCER CLUSTER 1 UP c2.IZADPANAH STEM CELL ADIPOSE VS BONE UP c2.WP EPITHELIAL TO MESENCHYMAL TRANSITION IN COLORECTAL CANCER c2.REACTOME CHREBP ACTIVATES METABOLIC GENE EXPRESSION c2.RIZUKA LIVER CANCER PROGRESSION G1 G2 UP				
c2.UNTERMAN IPF VS CTRL DC DN c2.REACTOME SUMOYLATION OF SUMOYLATION PROTEINS c2.REACTOME GERM LAYER FORMATION AT GASTRULATION c2.KRIGE RESPONSE TO TOSEDOSTAT 24HR UP c2.REACTOME DOWNSTREAM SIGNALING OF ACTIVATED FGFR2 c2.LIAO HAVE SOX4 BINDING SITES c2.HELLER SILENCED BY METHYLATION DN c2.NUYTTEN EZH2 TARGETS UP c2.REACTOME SYNAPTIC ADHESION LIKE MOLECULES c2.PUJANA BREAST CANCER LIT INT NETWORK c2.GILDEA METASTASIS c2.WP 2Q37 COPY NUMBER VARIATION SYNDROME c2.REACTOME CRISTAE FORMATION c2.TURASHVILI BREAST DUCTAL CARCINOMA VS LOBULAR NORMAL DN c2.MULLIGHAN NPM1 MUTATED SIGNATURE 1 DN				
c2.SCHAEFFER PROSTATE DEVELOPMENT 6HR UP c2.SUZUKI RESPONSE TO TSA c2.REACTOME ZINC TRANSPORTERS c2.REACTOME HYALURONAN UPTAKE AND DEGRADATION c2.WAKABAYASHI ADIPOGENESIS PPARG BOUND 8D c2.KANG FLUOROURACIL RESISTANCE UP c2.KEGG B CELL RECEPTOR SIGNALING PATHWAY c2.ZAIDI OSTEOBLAST TRANSCRIPTION FACTORS c2.WP INFLUENCE OF LAMINOPATHIES ON WNT SIGNALING c2.VANTVEER BREAST CANCER ESR1 UP c2.HOLLERN SOLID NODULAR BREAST TUMOR DN c2.WP WNTBETACATENIN SIGNALING IN LEUKEMIA c2.DORN ADENOVIRUS INFECTION 48HR UP c2.NAGY STAGA COMPONENTS HUMAN c2.KEGG RNA POLYMERASE				
c2.WP PHOTODYNAMIC THERAPYINDUCED AP1 SURVIVAL SIGNALING c2.REACTOME AZATHIOPRINE ADME c2.WU SILENCED BY METHYLATION IN BLADDER CANCER c2.WP NGLYCAN BIOSYNTHESIS c2.HUPER BREAST BASAL VS LUMINAL UP c2.ELVIDGE HYPOXIA UP c2.HEIDENBLAD AMPLICON 12P11 12 UP c2.REACTOME REGULATION OF CDH11 FUNCTION c2.DOUGLAS BMI1 TARGETS DN c2.PUJANA XPRSS INT NETWORK c2.WANG METHYLATED IN BREAST CANCER c2.LEONARD HYPOXIA c2.KEGG AMYOTROPHIC LATERAL SCLEROSIS ALS c2.LEE NEURAL CREST STEM CELL UP c2.KEGG MEDICUS REFERENCE AHR SIGNALING PATHWAY				
C2.LUI THYROID CANCER CLUSTER 2 C2.WP FOCAL ADHESION PI3KAKTMTORSIGNALING C2.REACTOME TP53 REGULATES TRANSCRIPTION OF CELL CYCLE GENES C2.WP AMINO ACID METABOLISM C2.NATSUME RESPONSE TO INTERFERON BETA UP C2.PAPASPYRIDONOS UNSTABLE ATEROSCLEROTIC PLAQUE DN C2.BIOCARTA MTA3 PATHWAY C2.RUTELLA RESPONSE TO HGF VS CSF2RB AND IL4 DN C2.MITSIADES RESPONSE TO APLIDIN UP C2.REACTOME BRANCHED CHAIN AMINO ACID CATABOLISM C2.ENK UV RESPONSE EPIDERMIS UP C2.STEIN ESRRA TARGETS C2.BONOME OVARIAN CANCER POOR SURVIVAL DN C2.KEGG MEDICUS PATHOGEN HTLV 1 TAX TO SRF MEDIATED TRANSCRIPTION C2.KOKKINAKIS METHIONINE DEPRIVATION 48HR UP C2.BIOCARTA RELA PATHWAY				
c2.PID BMP PATHWAY c2.RHODES UNDIFFERENTIATED CANCER c2.REACTOME INCRETIN SYNTHESIS SECRETION AND INACTIVATION c2.WP PHOSPHATIDYL INOSITOL PHOSPHATE PATHWAY c2.KEGG MEDICUS REFERENCE EGF EGFR PI3K SIGNALING PATHWAY c2.KIM MYC AMPLIFICATION TARGETS UP c2.OISHI CHOLANGIOMA STEM CELL LIKE UP c2.DAUER STAT3 TARGETS UP c2.WP NONGENOMIC ACTIONS OF 125 DIHYDROXYVITAMIN D3 c2.KEGG SMALL CELL LUNG CANCER c2.TURASHVILI BREAST DUCTAL CARCINOMA VS LOBULAR NORMAL UP c2.KEGG MEDICUS PATHOGEN HIV GP120 TO TNF NFKB SIGNALING PATHWAY c2.REACTOME FCERI MEDIATED CA 2 MOBILIZATION c2.RASHI RESPONSE TO IONIZING RADIATION 5 c2.DAVICIONI TARGETS OF PAX FOXO1 FUSIONS DN				
C2.DAVICIONI TARGETS OF PAX FOXOT FUSIONS DIN  C2.REACTOME PI 3K CASCADE FGFR4  C2.WENG POR TARGETS GLOBAL DN  C2.REACTOME CARBOXYTERMINAL POST TRANSLATIONAL MODIFICATIONS OF TUBULIN  C2.REACTOME NR1H2 NR1H3 REGULATE GENE EXPRESSION LINKED TO LIPOGENESIS  C2.MCDOWELL ACUTE LUNG INJURY DN  C2.REACTOME REGULATION OF KIT SIGNALING  C2.MAGRANGEAS MULTIPLE MYELOMA IGG VS IGA DN  C2.WP PI3KAKTMTOR VITAMIN D3 SIGNALING  C2.ROSS AML WITH PML RARA FUSION  C2.VANOEVELEN MYOGENESIS SIN3A TARGETS  C2.WP CANONICAL NFKB PATHWAY  C2.REACTOME RNA POLYMERASE III TRANSCRIPTION INITIATION FROM TYPE 1 PROMOTER  C2.PID CD40 PATHWAY  C2.RODRIGUES NTN1 AND DCC TARGETS				
c2.MATZUK POSTIMPLANTATION AND POSTPARTUM c2.BROWNE HCMV INFECTION 20HR UP c2.WP OVARIAN INFERTILITY c2.HOFMANN CELL LYMPHOMA UP c2.SCHRAETS MLL TARGETS UP c2.REACTOME DOPAMINE NEUROTRANSMITTER RELEASE CYCLE c2.BIOCARTA PCAF PATHWAY c2.CHEOK RESPONSE TO MERCAPTOPURINE DN	-			
c2.PAL PRMT5 TARGETS DN c2.TURASHVILI BREAST CARCINOMA DUCTAL VS LOBULAR UP c2.REACTOME INTEGRATION OF PROVIRUS c2.GARGALOVIC RESPONSE TO OXIDIZED PHOSPHOLIPIDS YELLOW UP c2.KEGG MEDICUS REFERENCE ACTH CORTISOL SIGNALING PATHWAY c2.KEGG MEDICUS REFERENCE HGF MET PI3K SIGNALING PATHWAY c2.HOLLMANN APOPTOSIS VIA CD40 DN c2.TERAMOTO OPN TARGETS CLUSTER 5				
C2.TURASHVILI BREAST CARCINOMA DUCTAL VS LOBULAR UP C2.REACTOME INTEGRATION OF PROVIRUS C2.GARGALOVIC RESPONSE TO OXIDIZED PHOSPHOLIPIDS YELLOW UP C2.KEGG MEDICUS REFERENCE ACTH CORTISOL SIGNALING PATHWAY C2.KEGG MEDICUS REFERENCE HGF MET PI3K SIGNALING PATHWAY C2.TERAMOTO OPN TARGETS CLUSTER 5 C2.TOMIDA LUNG CANCER POOR SURVIVAL C2.BERENJENO TRANSFORMED BY RHOA UP C2.KRIEG HYPOXIA NOT VIA KDM3A C2.WP THYROXINE THYROID HORMONE PRODUCTION C2.MULLIGHAN NPM1 SIGNATURE 3 UP C2.VANDESLUIS COMMD1 TARGETS GROUP 4 DN C2.HAHTOLA MYCOSIS FUNGOIDES CD4 UP C2.WHITFIELD CELL CYCLE G2 M C2.KEGG MEDICUS PATHOGEN EBV EBNA3C TO P53 MEDIATED TRANSCRIPTION C2.BROWNE HCMV INFECTION 1HR UP C2.PID P38 GAMMA DELTA PATHWAY C2.REACTOME SYNTHESIS OF VERY LONG CHAIN FATTY ACYL COAS C2.WP PHOTODYNAMIC THERAPYINDUCED NFE2L2 NRF2 SURVIVAL SIGNALING C2.SCIBETTA KDM5B TARGETS DN C2.WP 15Q112 COPY NUMBER VARIATION SYNDROME				
C2.TURASHVILI BREAST CARCINOMA DUCTAL VS LOBULAR UP C2.REACTOME INTEGRATION OF PROVIRUS C2.GARGALOVIC RESPONSE TO OXIDIZED PHOSPHOLIPIDS YELLOW UP C2.KEGG MEDICUS REFERENCE ACTH CORTISOL SIGNALING PATHWAY C2.KEGG MEDICUS REFERENCE HGF MET PISK SIGNALING PATHWAY C2.KEGG MEDICUS REFERENCE HGF MET PISK SIGNALING PATHWAY C2.KEGG MEDICUS REFERENCE HGF MET PISK SIGNALING PATHWAY C2.HOLLMANN APOPTOSIS VIA CD40 DN C2.TERAMOTO OPN TARGETS CLUSTER 5 C2.TOMIDA LUNG CANCER POOR SURVIVAL C2.BERENJEND TRANSFORMED BY RHOA UP C2.KRIEG HYPOXIA NOT VIA KOMSA C2.WP THYROXINE THYROID HORMONE PRODUCTION C2.MPLICHAN NPM1 SIGNATURE 3 UP C2.VANDESLUIS COMMOIT TARGETS GROUP 4 DN C2.HAHTOLA MYCOSIS FUNGOIDES CD4 UP C2.WHITFIELD CELL CYCLE G2 M C2.KEGG MEDICUS PATHOGEN EBV EBNA3C TO P53 MEDIATED TRANSCRIPTION C2.BROWNE HCMY INFECTION 1 HR UP C2.REACTOME SYNTHESIS OF VERY LONG CHAIN FATTY ACYL COAS C2.WP PHOTODYNAMIC THERAPYINDUCED NEF2L2 NRF2 SURVIVAL SIGNALING C2.SCIBETTA KOMSB TARGETS DN C2.WP PHOTODYNAMIC THERAPYINDUCED NEF2L2 NRF2 SURVIVAL SIGNALING C2.SCIBETTA KOMSB TARGETS DN C2.WP AUTOPHAGY C2.REACTOME GALPHA Z SIGNALLING EVENTS C2.REACTOME GALPHA Z SIGNALLING EVENTS C2.REACTOME MRNA DECAY BY 5 TO 3 EXORIBONUCLEASE C2.WP AUTOPHAGY C2.REACTOME MRNA DECAY BY 5 TO 3 EXORIBONUCLEASE C2.WP AUTOPHAGY C2.REACTOME MRNA DECAY BY 5 TO 3 EXORIBONUCLEASE C2.WP AUTOPHAGY C2.REACTOME STATS ACTIVATION DOWNSTREAM OF FLIT3 ITD MUTANTS C2.REACTOME STATS ACTIVATION DOWNSTREAM OF FLIT3 ITD MUTANTS C2.REACTOME STATS ACTIVATION OF GABA NEUROTRANSMISSION C2.REACTOME STATS ACTIVATION OF GABA NEUROTRANSMISSION C2.REACTOME MOLECULES ASSOCIATED WITH ELASTIC FIBRES C2.WP AUTOPHASIS C2.WP AUTOPHASISSION C2.REACTOME MOLECULES ASSOCIATED WITH ELASTIC FIBRES C2.WP AUTOPHASISSION C2.REACTOME MOLECULES ASSOCIATED WITH ELASTIC FIBRES C2.WP AVON GUIDANCE C2.REACTOME MOLECULES ASSOCIATED WITH ELASTIC FIBRES C2.WP AVON GUIDANCE C2.REACTOME MOLECULES ASSOCIATED WITH ELASTIC FIBRES C2.WP AVON GUIDANCE C2.WP AVON GUIDANCE C2.REACTOME MOLECULES ASSOCIATED WITH ELASTIC FIB				
C2.TURASHVILI BREAST CARCINOMA DUCTAL VS LOBULAR UP  22.REAGNEDICUS REFORDE INTEGRATION OF PROVIRUS  C2.AGRGALOVIC RESPONSE TO OXIDIZED PHOSPHOLIPIDS YELLOW UP  C2.KEGG MEDICUS REFERENCE ACT CONTISOL. SIGNALING PATHWAY  C2.KEGG MEDICUS REFERENCE ACT CONTISOL. SIGNALING PATHWAY  C2.KEGG MEDICUS REFERENCE HER MET PIKK SIGNALING PATHWAY  C3.CELLIMANN APPORTUS VIA COMBON TO TRANSFORMED BY RHOA UP  C2.KEGG MEDICUS PATHOGO TRANSFORMED BY RHOA UP  C2.KRIEG HYPOXIA NOT VIA KDMAS  C2.WP THYROXINE THYROID HORMONE PRODUCTION  C2.MULLIGHAN NPMI SIGNATURE 3 UP  C2.KARDESLUS COMMON TARRESTS GROUP 4 DN  C2.HANTOLA MYCOSIS FUNGOIDES CD4 UP  C2.KEGG MEDICUS PATHOGEN EBV EBNASC TO P53 MEDIATED TRANSCRIPTION  C2.KEGG MEDICUS PATHOGONE BV EBNASCRIPTION  C2.KEGG MEDICUS PATHOGONE BV EBNASCRIPTION  C2.KEGG WEDICUS PATHOGONE SYNTHESIS OF VERY LONG, GHAIN FATTY ACYL COAS  C2.WP PHOTODYNAMIC THERAPYINDUCED HER PICK JAMPS CANTUNAL SIGNALING  C2.WP ASSOCIATED FIRE ACT OF STANDARD CANTUNAL SIGNALING  C2.KEGG MEDICUS PATHOGONE SYNTHESIS OF VERY LONG, GHAIN FATTY ACYL COAS  C2.WP 150112 COPY LONG CHAIN FATTY ACYL COAS  C2.WP ASSOCIATED FIRE ACT OF STANDARD CANTUNAL SIGNALING  C2.KEGHELAVA MULTIPLE PRUG RESISTAND CANTUNAL SIGNALING  C2.KEGHELAVA MULTIPLE PRUG RESISTAND CANTUNAL SIGNALING  C2.KEGHELAVA MULTIPLE PRUG RESISTAND CANTUNAL SIGNALING  C2.REACTOME GALPHA Z SIGNALLING EVENTS  C2.REACTOME MRNA DECAY BY 5 TO 3 S CORRISON CLEASE  C2.MENER TARGETS OF MIRLETYAS UP  C2.REACTOME MRNA DECAY BY 5 TO 3 S CORRISON CLEASE  C2.MENER TARGETS OF MIRLETYAS UP  C2.REACTOME MRNA DECAY BY 5 TO 3 S CORRISON CLEASE  C2.MENER TARGETS ON THE SIGNALING PRUG SIGNALING HER SIGNALING SIGNALING SIGNALING HER SIGNALING SIGNALING HER SIGNALING SIGNALI				
c2.TURASHVILI BREAST CARCINOMA DUCTAL VS. LOBULAR UP  C2.GARCALOVIC REPONSES: REACTOME INTEGRATION OF PROVING  C2.GARCALOVIC REPONSES: CRACTOME INTEGRATION OF PROVING  C2.KEGG MEDICUS REFERENCE HOP PHOSPHOLIPIOS YELLOW UP  C2.KEGG MEDICUS REFERENCE HOP MICH PIGS SIGNALING PATHWAY  C2.KEGG MEDICUS REFERENCE HOP MICH PIGS SIGNALING PATHWAY  C2.TOMDA LUNG CANCER POOR SIGNALING PATHWAY  C2.MERICH PHOYALA NOT VIA KOMA  C2.WETHYROXINE THYROID HORMONE PROJUCTION  C2.WETHYROXINE THYROID HORMONE PROJUCTION  C2.WETHYROXINE THYROID HORMONE PROJUCTION  C2.WETHOR SIGNATURE 3 WE CANCER POOR SIGNALING PATHWAY  C2.WETHOR SIGNATURE SIGNALING PATHWAY  C2.WETHOR SIGNALING PATHWAY  C2.REACTOME MRNA DECAY SIGNALING PATHWAY  C2.REACTOME STATS ACTIVATION DOWNSTREAM OF SIGNALING PATHWAY  C2.REACTOME STATS ACTIVATION DOWNSTREAM OF SIGNALING PATHWAY  C2.REACTOME STATS ACTIVATION DOWNSTREAM OF SIGNALING PATHWAY  C2.REACTOME MOUST STATS ACTIVATION OF GABA NEUROTRANSMISSION  C2.REACTOME MOUST STATS ACTIVATION OF GABA NEUROTRANSMISSION  C2.REACTOME MOUST STATS ACTIVATION OF SIGNALING PATHWAY  C2.REACTOME MOUST STATS SIGNALING				
C2.TURASHYILI BREAST CARCINOMA DUCTAL VS LOBULAR UP  2.GARACA, MOVE RESPONSE, CRACTOME INTEGRATION OF PROVINGE  2.CARGE MEDICUS REFERENCE ACT IT CORTISOL SIGNALING PATHWAY  2.KEGG MEDICUS REFERENCE ACT IT CORTISOL SIGNALING PATHWAY  2.KEGG MEDICUS REFERENCE HOF HER PICK SIGNALING PATHWAY  2.KEGG MEDICUS REFERENCE HOR HER PICK SIGNALING PATHWAY  2.KEGG MEDICUS REFERENCE HOR HER PICK SIGNALING PATHWAY  2.KEGG MEDICUS REFERENCE HOR HER PICK SIGNALING PATHWAY  2.KEGG MEDICUS PATHOGEN BEY CANCELLED TO SURVINAL  2.KEGG MEDICUS PATHOGEN BEY CANCELLED TO SURVINAL  2.KEGG MEDICUS PATHOGEN BEY EMAN TO PEST SURVINAL SIGNALING  2.KEGG MEDICUS PATHOGEN BEY BERNAST OT PS SURVINAL SIGNALING  2.KEGG MEDICUS PATHOGEN BEY BERNAST OT PS SURVINAL SIGNALING  2.KEGG MEDICUS PATHOGEN BEY BERNAST OT PS SURVINAL SIGNALING  2.KEGG MEDICUS PATHOGEN BEY BERNAST OT PS SURVINAL SIGNALING  2.KEGG MEDICUS PATHOGEN BEY BERNAST OT PS SURVINAL SIGNALING  2.KEGG MEDICUS PATHOGEN BEY BERNAST OT PS SURVINAL SIGNALING  2.KEGG MEDICUS PATHOGEN BEY BERNAST OT PS SURVINAL SIGNALING  2.KEGG MEDICUS PATHOGEN BEY BERNAST OT PS SURVINAL SIGNALING  2.KEGG MEDICUS PATHOGEN BEY BERNAST OT PS SURVINAL SIGNALING  2.KEGG MEDICUS PATHOGEN BEY BERNAST OT PS SURVINAL SIGNALING  2.KEGG MEDICUS PATHOGEN BEY BERNAST OT PS SURVINAL SIGNALING  2.KEGG MEDICUS PATHOGEN BEY BERNAST OT PS SURVINAL SIGNALING  2.KEGG MEDICUS PATHOGEN BEY BERNAST OT PS SURVINAL SIGNALING  2.KEGG MEDICUS PATHOGEN BEY BERNAST OT PS SURVINAL SIGNALING EVENTS  2.KEGG MEDICUS PATHOGEN BERNAST OT PS SURVINAL SIGNALING EVENTS  2.KEGG MEDICUS PATHOGEN BERNAST OT PS SURVINAL SIGNALING EVENTS  2.KEGG MEDICUS PATHOGEN BERNAST OT PS SURVINAL SIGNALING EVENTS  2.KEGG MEDICUS PATHOGEN BERNAST OT PS SURVINAL SIGNALING EVENTS  2.KEGG MEDICUS PATHOGEN BERNAST OT PS SURVINAL SIGNALING EVENTS  2.KEGG MEDICUS PATHOGEN BERNAST OT PS SURVINAL SIGNALING EVENTS  2.KEGG MEDICUS PATHOGEN BERNAST OT PS SURVINAL SIGNALING EVENTS  2.KEGG MEDICUS REFERENCE PIT PT PT HER PS SIGNALING BERNAST SIGNALING PATHWAY  2.KEGG MEDICU				
C2. TURASHVILLI BERGST CARGINOMA DUCTAL, VS. LOBULAR ID.  C3. GARGALOURI REPERBORE ACTH CORTISOL. SIGNALING BATHWAY  C2. KEGO MEDICUS REPERBORE ACTH CORTISOL. SIGNALING BATHWAY  C2. KEGO MEDICUS REPERBORE ACTH CORTISOL. SIGNALING BATHWAY  C3. TERAMOTO OPIN TANGETS CLUSTERS.  C4. THE MENT AND				
CARRACTIONE STANDARD CONTROL SIGNALING PRINTING CARGO MEDICAL SEPTIMENT CATTOR CATTOR CATTOR CARGO MEDICAL SEPTIMENT CATTOR CATTOR CATTOR CARGO MEDICAL SEPTIMENT CATTOR				
CATALAS MILLIONES TO ANCIDADA DUCTAL VISI CORPUSATIONS GLORAGE CACCULAR TO RESPONSE OF CONCENTRATION CONTROL TO SET LANGUAGE CALLEGATOR CONCENTRATION CONTROL				
CARRESTORE PRESENT SECURIOR DUTCH, YOU CARREST AND CONTROL PRESENTS OF CONTROL PRESENT				
A LANGUAGE MATERIAL PROPERTY OF THE CONTRICATION OF THE CONTRICATI		25 0.00 0.25		